Skip to main content
. 2016 Feb 21;7(15):19680–19692. doi: 10.18632/oncotarget.7547

Figure 1. Expression and clinical significance of ZFX in colorectal cancer (CRC).

Figure 1

(A) Representative immunohistochemical staining of ZFX in CRC tissues (left) and their matched normal tissues (right) at 200× and 400× magnification. (B) Overall survival (OS) and disease-free survival (DFS) curves for a cohort of stage II/III CRC patients. (C) OS and DFS curves for stage II CRC patients who received no chemotherapy. (D) OS and DFS curves for stage II CRC patients who received chemotherapy. (E) OS and DFS curves of stage III CRC patients who received chemotherapy.